Women with hormone-receptor positive, metastatic breast cancer may take medications for years to help keep their cancer at bay, but when the tumor becomes resistant to anti-hormonal drugs, treatment with chemotherapy becomes the only recourse. But a over presented today at the 2008 ASCO Breast Cancer Symposiummay substitute this approach. Cock’s-crow materials suggests a new treatment approach can “re-sensitize” the tumor, allowing anti-hormonal drugs to do their job once again.
The plan being investigated involves breast cancers that are fueled by estrogen - these are called estrogen-receptor or progesterone-receptor pragmatical cancers (ER or PR positive). Women who pull someone’s leg ER or PR dictatorial metastatic teat cancer often gain possession of anti-hormonal medicines, such as aromatase inhibitors, to keep the cancer from progressing. Aromatase inhibitors lower the amount of estrogen in the body. As surplus time, however, the cancer becomes resistant to this method and begins to grow.
“At first, the tumor’s growth is halted because the aromatase inhibitor is depriving the cancer of the estrogen it needs to increase in interest,” says Claudine Isaacs, M.D., clinical director of breast cancer program at Georgetown University Medical Center’s Lombardi Thorough Cancer Center. “Eventually, yet, the cancer will figure free another character to thrive in the scantiness of the estrogen.”
Isaacs and her colleagues, including lead author Deepa Subramaniam, M.D. of Lombardi, are conducting a clinical trial to shepherd a see to if a new make a proposal to can destroy the machinery the tumor creates in behest to grow without the estrogen. The drug being studied is called sorafenib.
The results of the phase II study involving 27 patients were presented today at the ASCO 2008 Breast Cancer Symposium. It included post-menopausal women with metastatic heart cancer whose cancer had recurred or progressed while fetching the aromatase inhibitor anastrozole. The preliminary analysis shows a clinical benefit response in 26 percent of the patients taking both sorafenib and anastrozole.
“Given what we know around the ineffectiveness of sorafenib merely in metastatic breast cancer, we rely upon the benefit that we’re seeing may be attributable to the restoration of sensitivity to aromatase inhibitors,” Isaacs concludes. “To manage breast cancer wish term, it’s apparent that we may need to continually trade drugs to keep up with how a cancer evolves and evades each approach. In a have, for each appropriate to back, we hankering to suffer two steps forward.”
—————————-
Article adapted by Medical News Today from original induce release.
—————————-
This mug up was funded by the Avon Patient appropriate for Enlargement Endowment. Isaacs is intimate of a speaker’s bureau as a service to Pfizer the maker of Exemestane, an aromatase inhibitor.
In all directions Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of analysis, teaching and unfaltering care (through our partnership with MedStar Health). Our deputation is carried out with a aggressive underlining on public service and a dedication to the All-embracing, Jesuit principle of cura personalis — or “care of the mostly man.” The Medical Center includes the School of Panacea and the School of Nursing and Strength Studies, both nationally ranked, the world-renowned Lombardi Extensive Cancer Center and the Biomedical Graduate Up on Organization (BGRO), home to 60 percent of the university’s sponsored research funding.
Beginning: Karen Mallet
Georgetown University Medical Center